MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.50
-0.70
-3.15%
After Hours: 21.50 0 0.00% 16:00 06/17 EDT
OPEN
22.16
PREV CLOSE
22.20
HIGH
22.25
LOW
20.85
VOLUME
250.69K
TURNOVER
--
52 WEEK HIGH
58.48
52 WEEK LOW
15.51
MARKET CAP
1.01B
P/E (TTM)
-7.2763
1D
5D
1M
3M
1Y
5Y
Vaxcyte to Present at the Jefferies Virtual Healthcare Conference
FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly...
GlobeNewswire · 05/27 20:05
Ikarian Capital, LLC Buys Eli Lilly and Co, Macrogenics Inc, Galapagos NV, Sells Bristol-Myers ...
GuruFocus News · 05/17 12:38
Penn Mutual Asset Management, LLC Buys Kymera Therapeutics Inc, Elanco Animal Health Inc, ...
GuruFocus News · 05/13 19:38
Vaxcyte Q1 EPS $(0.41) Up From $(6.70) YoY
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(0.41) per share. This is a 93.88 percent increase over losses of $(6.70) per share from the same period last year.
Benzinga · 05/11 20:45
Vaxcyte EPS beats by $0.10
Vaxcyte (PCVX): Q1 GAAP EPS of -$0.41 beats by $0.10.Cash, cash equivalents and investments of $370.87M.Press Release
Seekingalpha · 05/11 20:42
Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update
FOSTER CITY, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly...
GlobeNewswire · 05/11 20:10
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 05/11 15:05
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 05/11 11:54
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PCVX. Analyze the recent business situations of Vaxcyte, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PCVX stock price target is 48.25 with a high estimate of 55.00 and a low estimate of 42.00.
EPS
Institutional Holdings
Institutions: 85
Institutional Holdings: 44.03M
% Owned: 94.18%
Shares Outstanding: 46.76M
TypeInstitutionsShares
Increased
38
3.88M
New
10
630.46K
Decreased
14
1.53M
Sold Out
17
1.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.27%
Key Executives
Chairman/Director
Kurt von Emster
Chairman/Director
Kurt Von Emster
President/Chief Financial Officer
Andrew Guggenhime
Chief Executive Officer/Co-Founder/Director
Grant Pickering
Co-Founder/Vice President
Jeff Fairman
Chief Operating Officer
Jim Wassil
Senior Vice President
Paul Sauer
Chief Compliance Officer/General Counsel/Secretary
Jane Wright-Mitchell
Director
Halley Gilbert
Director
Patrick Heron
Director
Peter Hirth
Director
Robert Hopfner
Director
Heath Lukatch
No Data
About PCVX
Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.

Webull offers kinds of Vaxcyte Inc stock information, including NASDAQ:PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.